CLDX
Celldex Therapeutics, Inc.NASDAQHealthcare$31.06-0.64%ClosedMarket Cap: $2.07B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.96
P/S
1392.12
EV/EBITDA
-7.41
DCF Value
$0.24
FCF Yield
-10.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-19160.0%
Net Margin
-17253.3%
ROE
-41.7%
ROA
-44.4%
ROIC
-53.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $75.0K | 100.0% | $-87.2M | $-81.4M | $-1.23 | — |
| FY 2025 | $1.5M | 100.0% | $-287.4M | $-258.8M | $-3.90 | — |
| Q3 2025 | $0.00 | NaN% | $-73.6M | $-67.0M | $-1.01 | — |
| Q2 2025 | $730.0K | 100.0% | $-63.9M | $-56.6M | $-0.85 | — |
| Q1 2025 | $695.0K | 100.0% | $-62.7M | $-53.8M | $-0.81 | — |
| Q4 2024 | $1.2M | 30.3% | $-56.0M | $-47.1M | $-0.71 | — |
| FY 2024 | $7.0M | -2229.8% | $-195.1M | $-157.9M | $-2.45 | — |
| Q3 2024 | $3.2M | 100.0% | $-52.1M | $-42.1M | $-0.64 | — |
| Q2 2024 | $2.5M | 68.1% | $-46.3M | $-35.8M | $-0.54 | — |
| Q1 2024 | $156.0K | -396.8% | $-40.6M | $-32.8M | $-0.56 | — |
| Q4 2023 | $4.1M | -636.5% | $-47.6M | $-43.3M | $-0.83 | — |
| FY 2023 | $6.9M | -1614.5% | $-154.5M | $-141.4M | $-2.92 | — |